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BASIC SCIENCES
Fibroblast Nox2 (NADPH Oxidase-2) Regulates 
ANG II (Angiotensin II)–Induced Vascular 
Remodeling and Hypertension via Paracrine 
Signaling to Vascular Smooth Muscle Cells
Craig B. Harrison, Silvia Cellone Trevelin, Daniel A. Richards , Celio X.C. Santos, Greta Sawyer, Andrea Markovinovic,  
Xiaohong Zhang, Min Zhang, Alison C. Brewer, Xiaoke Yin , Manuel Mayr , Ajay M. Shah
OBJECTIVE: The superoxide-generating Nox2 (NADPH oxidase-2) is expressed in multiple cell types. Previous studies 
demonstrated distinct roles for cardiomyocyte, endothelial cell, and leukocyte cell Nox2 in ANG II (angiotensin II)–induced 
cardiovascular remodeling. However, the in vivo role of fibroblast Nox2 remains unclear.
APPROACH AND RESULTS: We developed a novel mouse model with inducible fibroblast-specific deficiency of Nox2 (fibroblast-
specific Nox2 knockout or Fibro-Nox2KO mice) and investigated the responses to chronic ANG II stimulation. Fibro-Nox2KO 
mice showed no differences in basal blood pressure or vessel wall morphology, but the hypertensive response to ANG II infusion 
(1.1 mg/[kg·day] for 14 days) was substantially reduced as compared to control Nox2-Flox littermates. This was accompanied 
by a significant attenuation of aortic and resistance vessel remodeling. The conditioned medium of ANG II–stimulated primary 
fibroblasts induced a significant increase in vascular smooth muscle cell growth, which was inhibited by the short hairpin RNA 
(shRNA)-mediated knockdown of fibroblast Nox2. Mass spectrometric analysis of the secretome of ANG II–treated primary 
fibroblasts identified GDF6 (growth differentiation factor 6) as a potential growth factor that may be involved in these effects. 
Recombinant GDF6 induced a concentration-dependent increase in vascular smooth muscle cell growth while chronic ANG II 
infusion in vivo significantly increased aortic GDF6 protein levels in control mice but not Fibro-Nox2KO animals. Finally, silencing 
GDF6 in fibroblasts prevented the induction of vascular smooth muscle cell growth by fibroblast-conditioned media in vitro.
CONCLUSIONS: These results indicate that fibroblast Nox2 plays a crucial role in the development of ANG II–induced vascular 
remodeling and hypertension in vivo. Mechanistically, fibroblast Nox2 may regulate paracrine signaling to medial vascular 
smooth muscle cells via factors, such as GDF6.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: angiotensin II ◼ fibroblast ◼ hypertension ◼ NADPH oxidase-2 ◼ vascular remodeling
The arterial wall is a highly plastic structure with the capacity to adapt to changes in neurohumoral stimu-lation, blood pressure (BP), and flow during vascu-
lar diseases. This functional remodeling may involve all 
3 layers of the vessel—the intima, media, and adventitia. 
Chronic activation of the renin-angiotensin system plays 
a key role in vascular remodeling and hypertension. 
ANG II (angiotensin II)–induced vascular remodeling is 
a major contributor to the increase in peripheral vascular 
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resistance that characterizes hypertension.1 This remodel-
ing involves a significant thickening of the vascular media 
which is driven by vascular smooth muscle cell (VSMC) 
hypertrophy, accompanied at a cellular level by increased 
nuclear ploidy and DNA synthesis.2 ANG II–induced vas-
cular remodeling is also linked to an increased risk of 
other pathologies such as stroke.3 As such, inhibition of 
the renin-angiotensin system with angiotensin-converting 
enzyme inhibitors or ANG II receptor antagonists is a cor-
nerstone of antihypertensive therapy.4
A large body of evidence implicates reactive oxygen 
species (ROS) production in the pathophysiology of ANG 
II–dependent remodeling and hypertension.5,6 ROS have 
complex cell and context-specific roles in this setting, 
including pathophysiologic redox signaling that contributes 
to VSMC growth, effects on vessel tone, and actions in other 
organs, such as the kidney and brain.7–10 Nox (NADPH oxi-
dase) family proteins are major sources of vascular ROS 
in response to ANG II stimulation.11 Nox proteins mediate 
ROS production through catalytic subunits that transfer 
electrons from NADPH to molecular oxygen. Five distinct 
Nox enzymes (Nox1–5) with tissue-specific distribution 
and differing modes of activation have been identified, 
among which Nox1 and Nox2 are implicated in the devel-
opment of ANG II–induced hypertension in rodents.11 Mice 
globally deficient in Nox1 display a blunted hypertensive 
response to chronic ANG II infusion,8 whereas transgenic 
mice with VSMC-targeted overexpression of Nox1 develop 
exaggerated vascular remodeling and hypertension.12 
Mice with a global deficiency of Nox2 were also reported 
to develop less vascular remodeling and hypertension in 
response to chronic ANG II infusion.13,14 Although Nox1 
is expressed primarily in VSMC, Nox2 is found in several 
cell types including endothelial cells, fibroblasts, inflamma-
tory cells, and microglia.11 Recent studies have shown that 
Nox2 in endothelial cells, microglial cells, and leukocytes 
has distinct effects on ANG II–induced pathology and 
hypertension.10,15–17 For example, endothelial Nox2 acti-
vation is important in augmenting the early hypertensive 
response to chronic ANG II infusion, whereas myeloid cell 
Nox2 was found to modulate basal BP by reducing nitric 
oxide bioavailability.16 The potential role of Nox2 in fibro-
blasts is, however, unclear.
In this study, we developed a novel mouse model with 
fibroblast-specific deficiency of Nox2 to investigate the 
role of fibroblast Nox2 in ANG II–induced hypertension. 
The results show that fibroblast Nox2 plays a major role 
in the development of chronic ANG II–induced vascular 
remodeling and hypertension. These effects are governed 
at least in part by paracrine signaling involving the produc-
tion and release of GDF6 (growth differentiation factor 6) 
by Nox2-activated fibroblasts to induce VSMC growth.
METHODS
The authors declare that all supporting data are available within 
the article (and its Data Supplement).
Animals
Animal studies were performed in accordance with UK Home 
Office Guidance on the Operation of the Animals (Scientific 
Procedures) Act, 1986, and with institutional ethical approval. 
Nox2fl/fl mice on a C57BL/6J background were described 
recently.16 Fibroblast-specific Nox2 knockout (Fibro-Nox2KO) 
mice were generated by first crossing female Nox2fl/fl mice 
with male transgenic animals expressing a tamoxifen-induc-
ible Cre recombinase under the control of a fibroblast-spe-
cific regulatory enhancer element of the mouse Col1α2 gene 
(Col1α2CreER-Tg)18 also on a C57BL/6J background. Male 
Col1α2CreER/Nox2fl/y mice were compared with littermate 
male mice expressing Nox2fl/y without Col1α2CreER (“control” 
Nox2-Flox mice). We used male mice because this simplified 
the breeding strategy (as Nox2 is located on the X chromo-
some) and also to minimize estrogen-dependent fluctuations 
in response to ANG II.19 Both groups were treated with tamoxi-
fen (50 mg/kg IP, 10 days) at the age of 7 to 8 weeks to induce 
fibroblast-specific Nox2 deficiency in Col1α2CreER/Nox2fl/y 
mice (ie, Fibro-Nox2KO mice). Treatment with tamoxifen had 
no effect on cardiac function or BP in Col1α2CreER-Tg mice 
Nonstandard Abbreviations and Acronyms
Ad.shNox2  adenoviruses expressing shRNA tar-
geted against Nox2
ANG II angiotensin II
GDF6 growth differentiation factor 6
HTRA1 HtrA serine peptidase 1
LOXL2 lysyl oxidase homolog 2
Nox2 NADPH oxidase 2
ROS reactive oxygen species
SFRP1 secreted frizzled-related protein 1
TGF transforming growth factor
VSMC vascular smooth muscle cells
Highlights
• Nox2 (NADPH oxidase-2) is expressed in multiple cell 
types and is involved in cardiovascular remodeling but 
the role of fibroblast Nox2 is incompletely defined.
• Mice with a fibroblast-specific deficiency of Nox2 
display substantially reduced vascular remodeling 
and hypertension in response to chronic angioten-
sin II infusion.
• Fibroblast Nox2 regulates the paracrine release 
of GDF6 (growth differentiation factor 6) to exert 
growth effects on vascular smooth muscle cells.
• Fibroblast Nox2 plays a crucial role in the develop-
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(data not shown). Some Col1α2CreER-Tg mice were also 
crossed ROSA26R-tdTomatofl/fl mice (Jackson Labs).
In Vivo Procedures
Ambulatory BP was measured by radiotelemetry.16 Telemeters 
(model TA11PA-C10, Data Sciences International, 
Netherlands) were implanted subcutaneously under isoflu-
rane anesthesia, with the transducer inserted via the left 
carotid artery into the aorta. Flunixin-meglumine (5 mg/kg 
SC) was administered for analgesia. Measurements were 
made after a minimum 1-week recovery period. Analyses 
were performed using Dataquest ART software. ANG II 
(1.1 mg/[kg·day]) or vehicle were infused via subcutane-
ous osmotic minipumps (model 1002; Alzet, Cupertino, CA), 
implanted under 2% isoflurane. Echocardiography was per-
formed under 1% isoflurane anesthesia using a Vevo 2100 
System (VisualSonics, Toronto, Canada) equipped with a 22 
to 55 MHz linear-array transducer.16
Perfusion Fixation and Histology
Mice were terminally anesthetized with a pentobarbitone over-
dose and perfused via the left ventricle at ≈110 mm Hg, first 
with saline and then 4% paraformaldehyde. Aorta, carotid 
arteries, and hearts were dissected and frozen in optimal cut-
ting temperature compound before cryosectioning into 10 μm 
sections. Sections were stained with hematoxylin and eosin, 
dehydrated in ethanol, and cleared in xylene before cover-
slipping with distyrene plasticizer xylene mounting solution. 
Images were captured on a Zeiss AXIOSKOP microscope with 
×5 and ×10 objectives and analyzed using Volocity software 
(PerkinElmer, United Kingdom).
Immunofluorescence
Aorta was dissected, taking care not to lose the adventitia and 
frozen in optimal cutting temperature compound before making 
12 μm cryosections. Tissues were fixed with 4% paraformalde-
hyde, permeabilized with 0.2% Triton, and blocked with 3% BSA 
(bovine serum albumin) and 1.5% goat serum for 30 minutes 
each. Sections were incubated overnight with anti-Nox2 (2.5 
μg/mL, Catalog no. 611415; BD Biosciences), anti–smooth 
muscle actin (4 μg/mL, Catalog no. A2447; Sigma), anti-
vimentin (5 μg/mL, Catalog no. Ab8069; Abcam), WGA (wheat 
germ agglutinin)-rhodamine (20 μg/mL, Catalog no. RL1022S; 
Vector laboratories), anti-VE-cadherin (vascular endothelial cad-
herin; 10 μg/mL, Catalog no. 138002; Biolegend), anti-Ki67 
(1:200, Catalog no. NB-600-1252; Novus Biologicals), or anti-
GDF6 (10 μg/mL, Abcam, Catalog no. Ab73288) antibodies 
before washing and incubating with an Alexa-594 conjugated 
fluorescent secondary antibody (anti-rabbit for GDF6; anti-
mouse for smooth muscle actin or Nox2). Nuclei were stained 
with 4′-6-diamidino-2-phenylindole (Sigma). Images were cap-
tured on an Olympus 1X81-2 fluorescent microscope using a 
×40 objective or a Leica confocal TCS SP5 microscope using 
a ×63 objective. Analyses of mean fluorescence intensity and 
co-localization were performed using Image J software (v1.0 
Mac OS X; National Institutes of Health).
Brains were fixed with 4% paraformaldehyde for 16 hours 
and embedded in optimal cutting temperature compound, 
then cryosectioned into 25 μm coronal slices. The tissue was 
permeabilized with 0.25% Triton and blocked with 1% BSA and 
10% horse serum. After overnight incubation with anti-Nox2 
antibody and washing, slices were incubated with Alexa-555 
anti-rabbit antibody. Imaging was performed using an Olympus 
VS120 slide scanner and Nox2 optical density in the subforni-
cal organ was analyzed using Image J.
Immunoblotting
Sections of aorta were snap-frozen in liquid nitrogen, crushed 
with a micropestle, and protein was extracted using Laemmli 
buffer and sonication. Bone marrow cells were flushed in 
PBS (phosphate-buffered saline), centrifuged at 500g for 5 
minutes, and the pellet solubilized in RIPA (radioimmunopre-
cipitation assay) buffer (50 mmol/L Tris-HCl pH 7.2, 150 
mmol/L NaCl, 2 mmol/L EDTA, 1%Triton). The conditioned 
medium from ANG II–stimulated fibroblasts was dried and 
the pellet dissolved in Laemmli buffer. Immunoblots were 
performed using 4% to 12% sodium dodecyl sulfate (SDS)-
polyacrylamide gels and standard methods. Antibodies 
used were: Nox2 (0.25 μg/mL, Catalog No. 611415; BD 
Biosciences, United Kingdom), β-actin (0.67 μg/mL; Sigma, 
United Kingdom), GDF6 (1μg/mL; Abcam), and HTRA1 (ser-
ine protease HTRA1; 2 μg/mL, Abcam ab38611, United 
Kingdom). An LI-COR Odyssey system (LI-COR, NE) and 
secondary antibodies were used to reveal and quantify immu-
noreactive bands. Total protein was determined by an LI-COR 
Revert 700 staining Kit for Western Blot Normalization (Catalog 
no. P/N 926-11016) or Ponceau staining.
Real-Time Polymerase Chain Reaction
Whole aortas were homogenized in TRIzol reagent 
(ThermoFisher) for RNA extraction. Reverse transcription was 
performed using standard methods and polymerase chain reac-
tion was performed on an Applied Biosystems 7000 system 
(Applied Biosystems, United Kingdom) using SYBR Green and 
the comparative Ct (threshold cycle) method, with cytoskeletal 
β-actin levels used for normalization. Forward and reverse prim-
ers were as follows (all 5′-3):
β-actin Forward: CTGTCGAGTCGCGTCCACCC; Reverse: 
ATGCCGGAGCCGTTGTCGAC; TGF (transforming growth 
factor)-β1 Forward: TGGAGCAACATGTGGAACTC; Reverse: 
GTCAGCAGCCGGTTACCA; TGF-β2 Forward: AGGAGGTTT 
ATAAAATCGACATGC; Reverse: TAGAAAGTGGGCGGGATG; 
TGF-β3 Forward: GCAGACACAACCCATAGCAC; Reverse: 
GGGTTCTGCCCACATAGTACA; GDF6 Forward: TAGCTTCCT 
CTGGGATTTGC, Reverse: GAGGAGGAGGACGAGGAGAT; 
LOXL2 Forward: GGAGAACAAGGCATCACCAT, Reverse: 
GTTGGGGTTAATGCAAACCTG; SFRP1 Forward: CAGTTG 
TGGCTTTTGCATTG, Reverse: GAGGGAAGGGAGAGGGTT; 
HTRA1 (HtrA serine peptidase 1) Forward: 
CATTGAAGTCATTCCTGACAC, Reverse: 
TGTCCGTTGATGCTGATG; NOX2 Forward: CCAACTGGGAT 
AACGAGTTCAA, Reverse: TCAGGGCCACACAGGAAAA; 
p22phox Forward: TGGACGTTTCACACAGTGGTA, Reverse: 
TGGACCCCTTTTTCCTCTTTC; p67phox Forward: AAGCTGTT 
TGCCTGTGAGGT, Reverse: CTTCATGTTGGTTGCCAATG; 
p47phox Forward: AGAGTCGCCAGGGCACTCT, Reverse: TCTT 
CGCCTGGCTGTCAGT; Nox4 Forward: CCGGACAGTCCT 
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Forward: CGTGAAAAGATGACCCAGATCA, Reverse: TGGTA 
CGACCAGAGGCATACAG.
Cells
Primary cardiac fibroblasts were isolated, as previously 
described.20 They were seeded in 0.05% gelatin-coated cul-
ture flasks containing DMEM (Dulbecco’s modified Eagle’s 
medium; Sigma, D6546) supplemented with 10% FCS (fetal 
calf serum), penicillin, and streptomycin and maintained at 
37 °C in humidified 5% CO2. Fibroblasts were used at pas-
sage 1. Mouse aortic VSMC were isolated and maintained in 
10% FCS and 1% NAAA (α-napthaleneacetic acid) contain-
ing medium (Sigma: D5671) and studied at passage 2 to 3.21 
VSMC were seeded at 10 000 cells per well in 24 well plates or 
40 000 cells per well in 6 well plates 24 hours before the start 
of an experiment. Aortic fibroblasts were purchased from Cell 
Biologics (C57BL/6 mouse primary aortic fibroblasts; Catalog 
no. C57-6075) and cultured in complete fibroblast medium 
(Cell Biologics; Catalog no. M2267).
VSMC Growth Assays
Fibroblasts were treated with 200 nmol/L ANG II or vehicle 
in 0.1% FCS medium for 48 hours, after which the medium 
was removed and centrifuged at 310g for 5 minutes. In some 
experiments, fibroblasts were first transduced with adenovi-
ruses expressing shRNA (short hairpin RNA) targeted against 
Nox2 (Ad.shNox2) or adenoviruses expressing shRNA tar-
geted against a GFP (green fluorescent protein) control,10 
then treated with ANG II and the conditioned medium pre-
pared. Some fibroblasts were transfected with siRNA (silenc-
ing RNA) against GDF6 or scrambled siRNA (Catalog no. 
MBS8236943; MyBiosource) using lipofectamine 2000 24 
hours before stimulation with ANG II. VSMC seeded onto 
glass cover-slips were incubated with fibroblast-conditioned 
medium for 48 hours, then the cells were fixed and prepared 
for staining. In some experiments, VSMC were treated with 
recombinant GDF6 (PeproTech Human BMP-13/CDMP-2) 
for 24 hours before preparing for staining. Cells were incu-
bated with anti-ki67 (Vector: 1:100) and anti–smooth muscle 
actin (Sigma: 1:1000) antibodies for 1 hour at room tempera-
ture or were first treated with 10 μmol/L BrdU (bromodeoxy-
uridine; Sigma) per well and then incubated with anti-BrdU 
(10 μg/mL, Catalog no. ab152095; Abcam) and anti–smooth 
muscle actin (4 μg/mL, Catalog no. A2447; Sigma) antibodies. 
Cells were then washed and incubated with Alexa 568 conju-
gated anti-rabbit and Alexa 488 conjugated anti-mouse sec-
ondary antibodies, then 4′-6-diamidino-2-phenylindole before 
mounting onto microscope slides in FluoromountTM aqueous 
mounting medium (Catalog no. F4680; Sigma). Images were 
captured on an Olympus 1X81-2 fluorescent microscope and 
analyzed using Volocity software or a Leica TCS SP5 confocal 
microscope and analyzed using Image J.
Secretome Analysis
Primary fibroblasts in T25 culture flasks were infected with 
Ad.shNox2 or adenoviruses expressing shRNA targeted 
against a GFP control, then treated with ANG II (200 nmol/L) 
or vehicle in FCS-free medium for 48 hours. The medium 
was then removed, spun at 15 000g for 10 minutes, and the 
supernatant was collected and frozen at −80 °C. Proteomic 
analysis of the supernatants was performed by mass spec-
trometry as previously described.22 For immunoblot analyses, 
the conditioned medium was lyophilized before resuspending 
in Laemmli buffer.
TGF-β ELISA
Primary cardiac fibroblasts were treated with ANG II (200 
nmol/L) or vehicle for 2 days, then the ELISA (TGF-β1 ELISA 
kit, Catalog no. 88-8350-22; Affymetrix) was performed on the 
conditioned medium.
ROS Assay
Dihydroethidium fluorescence was used to estimate ROS pro-
duction in aorta. For this, 7-μm thick tissue sections were incu-
bated with 3 μmol/L dihydroethidium in Hank’s without phenol 
red, with diethylenetriamine-pentaacetic acid (100 μmol/L) 
for 30 minutes. Images were then obtained immediately on an 
Olympus 1X81 inverted epifluorescence microscope.
The dihydroethidium oxidation product, 2-hydroxyethidium, 
was quantified in aorta and cultures of fibroblasts as previously 
described.16 Aortae from mice chronically infused with ANG II 
or fibroblasts stimulated with ANG II (200 nmol/L, 4 hours) 
were incubated with dihydroethidium (100 μM) for 30 minutes 
at 37 °C and then lyophilized in acetonitrile. Quantification of 
2-hydroxyethidium was performed by high-performance liquid 
chromatography (HPLC).
Renal Function
Mice were challenged with 1 mL IP PBS, and the urine col-
lected hourly in a metabolic cage for 4 hours.16 Urine osmolar-
ity, sodium, and potassium concentrations were analyzed on an 
Advia 2400 Chemistry System (Siemens AG, Germany).
Statistics
Data are expressed as mean±SEM. The Kolmogorov-Smirnov 
normality test (with Dallal-Wilkinson-Lilliefor corrected P value) 
was used to test normality of the samples. Comparisons were 
made by Student unpaired t tests, 1-way ANOVA, or 2-way 
ANOVA followed by Tukey post hoc test or a nonparametric 
Kruskal-Wallis followed by Dunn post-test, as appropriate. Data 
were analyzed on GraphPad Prism v6. P<0.05 was considered 
significant.
RESULTS
Fibroblast-Specific Deletion of Nox2 In Vivo Has 
No Effect on Basal BP
Inducible deletion of fibroblast Nox2 was achieved 
by intraperitoneal injection of tamoxifen in adult 
Col1α2CreER/Nox2fl/y mice, to generate Fibro-Nox2KO 
animals. Fibro-Nox2KO mice showed evidence of Cre-
mediated recombination in DNA isolated from aorta (Fig-
ure 1A), as well as a significant decrease in Nox2 protein 
levels by Western blot (Figure 1B). There were no signifi-
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Figure 1. Basal phenotype of Fibro-Nox2KO mice.
A, Polymerase chain reaction showing Cre-mediated recombination in Fibro-Nox2KO (fibroblast-specific Nox2 knockout) aorta. B, Nox2 protein 
levels in aorta from Fibro-Nox2KO and control (Nox2Flox) mice. A representative immunoblot is shown along with mean data. n=7 per group. 
*P<0.05, unpaired Student t test. C, Immunofluorescence for Nox2 (Red) in aortic sections from Fibro-Nox2KO and control mice. Blue, nuclei 
stained with 4′-6-diamidino-2-phenylindole (DAPI); green, autofluorescence (AF) of the vessel wall. Scale bars, 50 µm. D, Systolic blood 
pressure (BP) and (E) heart rate measured by ambulatory telemetry in Fibro-Nox2KO and control mice (n=3 per group). F–I, Cardiac structure 
and function assessed by echocardiography. n=5–7 per group. IVST indicates interventricular septal thickness; L, vessel lumen; LVEDV, left 
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p67phox, Nox1, or Nox4 between Fibro-Nox2KO and con-
trol Nox2-Flox mouse aortae but mRNA levels of Nox2 
were significantly reduced (Figure IA through IF in the 
Data Supplement). Immunofluorescence of aortic sec-
tions revealed a marked reduction in Nox2 immunostain-
ing in the adventitia of the Fibro-Nox2KO group compared 
to control mice, whereas endothelial Nox2 staining was 
preserved (Figure 1C). Fibro-Nox2KO mice did not show 
differences in Nox2 protein levels in bone marrow cells 
as compared to Nox2-Flox mice (Figure IIA in the Data 
Supplement). To further assess the cell-specificity of the 
Col1α2CreER approach, we crossed Col1α2CreER mice 
with ROSA26R-tdTomatofl/fl mice, in which expression of 
tdTomato fluorescence is dependent on Cre-mediated 
excision of a STOP codon. In the progeny, tdTomato fluo-
rescence would, therefore, be expressed in cells targeted 
by the Col1α2 promoter and expressing Cre recombinase. 
Using this approach, tdTomato fluorescence in heart sec-
tions overlapped with vimentin staining in the adventitia 
of coronary vessels (used as a fibroblast marker) but not 
at the lumen in the endothelium (Figure IIB in the Data 
Supplement). Furthermore, there was no overlap between 
tdTomato fluorescence and VE-cadherin, used as an 
endothelial marker (Figure IIC in the Data Supplement). 
Taken together, these results indicate the Col1α2CreER 
approach results in fibroblast-specific genetic targeting.
There was no difference between Fibro-Nox2KO and 
control mice in body or organ weights and no obvious 
basal phenotype (data not shown). Ambulatory systolic 
BP, diastolic BP, and heart rates were similar in the two 
groups under baseline conditions (Figure 1D). Cardiac 
dimensions and function assessed by echocardiography 
were also unaltered in Fibro-Nox2KO mice compared 
with control (Figure 1F through 1I).
ANG II–Induced Hypertension and Vascular 
Remodeling Are Inhibited in Fibro-Nox2KO Mice
We next tested the BP response to chronic 2-week 
ANG II infusion in Fibro-Nox2KO and control mice, using 
ambulatory telemetry. Although control mice developed a 
significant increase in systolic, mean, and diastolic BP by 
the end of 2-week infusion, this response was markedly 
blunted in Fibro-Nox2KO animals (Figure 2A through 
2C). There was no difference in heart rate between 
groups (Figure 2D). Aortic sections from Fibro-Nox2KO 
mice infused with ANG II showed a lower dihydroethid-
ium fluorescence signal than those from control mice 
under the same treatment, and levels of the dihydro-
ethidium oxidation product 2-hydroxyethidium measured 
by HPLC in aortic homogenate were also significantly 
reduced (Figure IIIA and IIIB in the Data Supplement). 
Moreover, fibroblasts isolated from Fibro-Nox2KO mice 
showed lower 2-hydroxyethidium levels than cells from 
Nox2-Flox mice after in vitro stimulation with ANG II 
(Figure IIIC in the Data Supplement).
Assessment of renal function with an intraperitoneal 
saline challenge test revealed no significant differences 
in urine osmolarity, sodium, or potassium concentration 
in Fibro-Nox2KO mice compared to controls (Figure IV 
in the Data Supplement). However, aortic sections from 
control mice that had received 2-week ANG II infusion 
showed a significant increase in medial area and media/
lumen ratio, whereas these changes were inhibited in 
Fibro-Nox2KO mice (Figure 3A through 3C). There were 
no differences in medial area between vehicle-treated 
groups. To assess whether similar changes occurred in 
smaller resistance arteries, we analyzed carotid arteries 
and small septal arteries in myocardial sections. A similar 
inhibition of medial thickening to that observed in the aorta 
was also found in carotid arteries (Figure 3D through 3E) 
and septal arteries (Figure 3F through 3G) of ANG II–
treated Fibro-Nox2KO mice compared with controls.
Since Nox2 activation in the subfornical organ of the 
brain is also implicated in mediating the hypertension 
induced by ANG II infusion,10 we evaluated Nox2 expres-
sion in the subfornical organ by immunostaining of brain 
sections. These studies showed that Nox2 immunostain-
ing was similar in FibroNox2KO and Nox2-Flox brain sub-
fornical organ (Figure V in the Data Supplement). Brain 
sections from global Nox2 KO mice and sections stained 
with nonspecific IgG were used as controls. Therefore, 
Nox2 levels in the subfornical organ do not appear to be 
altered in FibroNox2KO mice.
Nox2 Deficiency in Fibroblasts Inhibits ANG 
II–Induced Vascular Smooth Muscle Growth
The increase in vascular medial thickness after ANG 
II infusion is thought to reflect an increase in VSMC 
growth and hypertrophy.1,2 To investigate whether defi-
ciency of Nox2 in fibroblasts affects ANG II–induced 
VSMC growth, we first assessed medial VSMC growth 
in aortic sections by counting the number of nuclei of 
smooth muscle actin-positive cells in the medial layer 
(since VSMC hypertrophy is accompanied by increased 
ploidy2). This analysis revealed a nearly 50% increase 
in the number of nuclei in Ang II–treated compared to 
vehicle-treated control mice (Figure 4A). However, aortic 
sections of ANG II–treated Fibro-Nox2KO mice showed 
a significantly smaller increase in number of nuclei, sug-
gesting that deficiency of Nox2 in fibroblasts affects 
VSMC growth during ANG II stimulation.
To more directly investigate a potential effect of fibro-
blasts on VSMC growth, we next assessed the response of 
cultured VSMC to incubation with the conditioned medium 
of primary cardiac fibroblasts treated with ANG II or vehicle. 
VSMC growth was assessed by the quantification of ki67 
staining or BrdU incorporation (which assess DNA synthe-
sis) and was found to be significantly increased by incubation 
with the conditioned medium of ANG II–treated fibroblasts 
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response, fibroblasts were transduced with Ad.shNox2 or 
adenoviruses expressing shRNA targeted against a GFP 
control before treatment with ANG II and the collection 
of conditioned medium. Fibroblast Nox2 protein levels 
were substantially reduced by infection with Ad.shNox2 
(Figure 4C). We found that the increase in VSMC growth 
induced by fibroblast-conditioned medium was substantially 
inhibited by the knockdown of Nox2 (Figure 4D). Similar 
results were obtained with conditioned media obtained 
from aortic fibroblasts (Figure VI in the Data Supplement). 
The incubation of fibroblasts with catalase and superoxide 
dismutase before collection of conditioned media also sig-
nificantly reduced the ability of the media to induce VSMC 
growth in vitro (Figure 4E). These results suggest that Nox2 
modulates the paracrine effects of fibroblasts on VSMC 
growth in a redox-dependent manner.
Identification of GDF6 as a Nox2-Dependent 
Growth Factor Secreted by Fibroblasts
The treatment of fibroblast-conditioned medium with 
catalase did not alter its effects on VSMC growth (Figure 
VII in the Data Supplement), indicating that the response 
does not depend upon the presence of hydrogen perox-
ide in the medium (ie, does not involve the direct effects 
of hydrogen peroxide). To assess whether the fibroblast-
conditioned medium contains factors that may mediate its 
effects on VSMC growth, we analyzed the secretome of 
ANG II–treated fibroblasts by mass spectrometry. A total 
of 460 proteins were identified of which 201 were pre-
dicted to be extracellular and potentially secreted, using 
DAVID bioinformatic software 6.7 (Figure VIIIA and VIIIB 
in the Data Supplement). To narrow down fibroblast-
specific secreted factors, these proteins were compared 
to the mouse VSMC secretome profile22 using VENNY 
(http://bioinfogp.cnb.csic.es/tools/venny/). This analysis 
identified 121 fibroblast-secreted proteins that are not 
abundantly secreted by primary mouse VSMC (Figure 
VIIIC in the Data Supplement). We then performed gene 
ontology enrichment on these proteins and looked for 
those that have previously been reported to have growth 
properties (Figure IX in the Data Supplement). Based 
on this analysis, 6 proteins were highlighted for further 
investigation—namely, SFRP1 (secreted frizzled-related 
Figure 2. ANG II (angiotensin II)–induced hypertension is inhibited in Fibro-Nox2KO mice.
Telemetric ambulatory blood pressure (BP) in fibroblast-specific Nox2 knockout (Fibro-Nox2KO) and matched control (Nox2Flox) mice treated 
with chronic ANG II infusion or saline. A, Systolic BP (BP); (B) diastolic BP; (C) mean arterial BP; (D) heart rate. 2-way repeated-measures 
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Figure 3. ANG II (angiotensin II)–induced vascular remodeling is inhibited in Fibro-Nox2KO mice.
Control (Nox2Flox) and fibroblast-specific Nox2 knockout (Fibro-Nox2KO) mice were chronically treated with ANG II or vehicle, then perfusion-
fixed. A, Representative aortic sections. Scale bars, 100 µm. B, Mean aortic medial area and (C) media/lumen ratio; n=4–6 aortae per group. 
D, Representative sections of carotid artery. Scale bars, 100 µm. E, Mean medial area of carotid artery sections; n=3–6 arteries per group. 
F, Representative myocardial sections showing small septal arteries. Scale bars, 50 µm. G, Mean media/lumen ratio of septal arteries; n=4–6 
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protein 1), LOXL2 (lysyl oxidase homolog 2), HTRA1, 
GDF6, TGF-β1, and TGF-β3.
We quantified the ANG II–induced changes in gene 
expression of these proteins in fibroblasts transduced with 
Ad.shNox2 or adenoviruses expressing shRNA targeted 
against a GFP control. ANG II significantly increased the 
mRNA levels of GDF6, TGF-β1, and HTRA1 in control 
fibroblasts, but this response was markedly blunted in 
Nox2-deficient fibroblasts (Figure X in the Data Supple-
ment). There were no significant differences between 
groups in SFRP1 or LOXL2. Based on this analysis, we 
quantified protein levels of GDF6, HTRA1, and TGF-β1 
in the conditioned medium of ANG II or saline-treated 
fibroblasts deficient in Nox2 as compared to control 
fibroblasts. We did not find differences in HTRA1 levels 
between groups by immunoblotting (Figure XI in the Data 
Figure 4. Fibroblast Nox2 (NADPH oxidase-2) is required for ANG II (angiotensin II)–induced vascular smooth muscle cell 
(VSMC) growth.
A, Increased VSMC ploidy in aortic media of ANG II–treated control (Nox2Flox) vs fibroblast-specififc Nox2 knockout (Fibro-Nox2KO) mice. 
Representative aortic sections examined by immunofluorescence are shown to the left. Red, α-smooth muscle actin; blue, 4′-6-diamidino-2-
phenylindole (DAPI; nucleus); green, autofluorescence (AF). Scale bars, 50 µm. Mean data for number of DAPI-positive nuclei/100 µm of media 
shown to the right; n=3–5 aortae per group. B, Effect of ANG II–conditioned cardiac fibroblast medium on VSMC growth, assessed by Ki67 
staining or BrdU (bromodeoxyuridine) incorporation, respectively; n=4 per group. C, Knockdown of Nox2 in cardiac fibroblasts by adenoviruses 
expressing shRNA (short hairpin RNA) targeted against Nox2 (Ad.shNox2) compared with adenoviruses expressing shRNA targeted against 
GFP (green fluorescent protein) control (Ad.shGFP). Representative immunoblot at the top shows Nox2 knockdown; mean data for Nox2 
protein levels are shown below; n=8 per group. D, Conditioned medium from fibroblasts treated with Ad.shNox2 has reduced growth activity 
on VSMC as assessed by BrdU incorporation; n=7–9 per group. E, Preincubation of fibroblasts with SOD (PEG-superoxide dismutase) and 
CAT (PEG-catalase) prevents the effect of conditioned media on VSMC growth. n=3 per group. Unpaired Student t test (B and C) or 1-way 
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Supplement) and could not detect TGF-β1 in fibroblast-
conditioned media using ELISA (Figure XII in the Data 
Supplement). However, GDF6 protein levels in the control 
fibroblast secretome were significantly increased by ANG 
II treatment, and this response was inhibited in Nox2-
deficient fibroblasts (Figure 5A and Figure XI in the Data 
Supplement). To confirm the in vivo relevance of this find-
ing, GDF6 levels were assessed in aorta of Fibro-Nox2KO 
and control mice with and without chronic ANG II treat-
ment. Western blot analysis showed that ANG II treatment 
resulted in a significant increase in aortic GDF6 levels 
in control mice but this was markedly blunted in Fibro-
Nox2KO animals (Figure 5B). Immunostaining of aortic 
sections also confirmed a substantial increase in GDF6 
levels in ANG II–treated control mice, with a much smaller 
increase in Fibro-Nox2KO aorta (Figure 5C).
Next, the effects of recombinant GDF6 were tested 
on cultured VSMC. GDF6 induced a dose-dependent 
increase in VSMC growth as assessed by BrdU incor-
poration (Figure 6A). Additionally, silencing GDF6 in 
aortic or cardiac fibroblasts (Figure 6B) reduced the 
ability of the conditioned media from ANG II–treated 
cells to induce VSMC growth (Figure 6C and 6D). Taken 
together, these results suggest that the Nox2-dependent 
effects of fibroblasts on VSMC growth are mediated to a 
significant extent by GDF6.
DISCUSSION
This study identifies a crucial role of fibroblast Nox2 in 
the development of Ang II–induced vascular remodeling 
and hypertension. We uncover a novel Nox2-regulated 
paracrine-signaling mechanism involving the release of 
GDF6, through which fibroblasts control VSMC growth in 
the setting of ANG II stimulation. These results strengthen 
the emerging paradigm that Nox2 has cell-specific func-
tions and its activation contributes to ANG II–induced 
vascular remodeling and hypertension through distinct 
molecular mechanisms.
A role for adventitial fibroblasts in regulating vascu-
lar functions has been reported in previous work.23 Our 
results are consistent with previous findings that Nox2 
contributes to ROS production in mouse aortic fibro-
blasts but not VSMC.24 Another study showed that Nox2 
oxidase is expressed in adventitial fibroblasts and may 
regulate vascular tone by reducing nitric oxide bioavail-
ability.25 In addition, fibroblast Nox2 signaling was sug-
gested to influence vascular inflammation and potentially 
contribute to pathologies such as aortic aneurysm forma-
tion.26 However, whether fibroblast Nox2 has any specific 
role in the development of ANG II–induced hypertension 
and associated vascular remodeling, and what underlying 
mechanisms may be involved, has been unclear. In the 
present study, the development and analysis of a new 
fibroblast-specific Nox2 knockout mouse model allowed 
us to definitively demonstrate a major role of fibroblast 
Nox2 in ANG II–induced hypertension.
An increase in peripheral vascular resistance resulting 
from the remodeling of resistance arteries is recognized to 
be an important contributing factor to hypertension, both 
in animal models and humans.1,2 The vascular remodeling 
that occurs during ANG II–induced hypertension is charac-
terized by an increase in medial area and the media/lumen 
ratio.8,12,13 We found that the inhibition of ANG II–induced 
hypertension in Fibro-Nox2KO mice was accompanied 
by a substantial reduction in vascular medial thickening 
and media/lumen ratio, which was observed not only in 
the aorta but also in smaller resistance vessels in 2 other 
vascular beds. These findings suggest that the differences 
in BP between Fibro-Nox2KO and control mice are very 
likely to be driven by the differences in vascular remodel-
ing. We did not however find any effect of fibroblast Nox2 
deficiency on basal BP. These effects contrast to those 
recently reported in mouse models of endothelial-specific 
or myeloid cell–specific Nox2 knockout. It was found that 
myeloid cell Nox2 modulates basal BP through changes in 
vascular tone but has minimal effects on ANG II–induced 
hypertension.16 However, endothelial cell Nox2 did not 
affect basal BP but contributed to the early phases (the 
first 5 days) of ANG II–induced hypertension via ROS-
induced changes in vessel tone.16 In the current study, it 
was notable that the effects of fibroblast Nox2 on ANGI 
II–induced hypertension were most evident towards the 
end of infusion (after at least 1 week), consistent with a 
mechanism that involves gradual thickening of the vas-
cular media. Therefore, it is likely that Nox2 in different 
cell types contributes to ANG II–induced hypertension in 
mice through different mechanisms that are effective at 
different stages of the development of hypertension in 
this model. Interestingly, a previous study that conditionally 
targeted AT1 (angiotensin type 1) receptors in different 
cell types in mice in vivo reported that ANG II–induced 
aortic medial thickening involves AT1 receptors on adven-
titial fibroblasts rather than on VSMC or endothelial cells.27 
The current findings in the Fibro-Nox2KO mice are, there-
fore, consistent with these previous results and support 
a fibroblast-mediated mechanism for vascular remodeling 
induced by ANG II. The precise relationship between the 
vascular remodeling and hypertension or the longer-term 
impact of the changes in vascular remodeling on ANG II–
induced hypertension was not investigated in our study 
and therefore remain speculative.
To investigate the mechanism by which fibroblast Nox2 
affects remodeling of the vascular media, we hypothesized 
that it involves a paracrine effect of fibroblasts on VSMC 
growth. Consistent with this notion, there was evidence of 
significantly increased medial VSMC growth in the aorta 
after chronic ANG II infusion in control mice, which was 
not observed in Fibro-Nox2KO animals. Furthermore, the 
conditioned medium of ANG II–stimulated cultured fibro-
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Figure 5. Nox2 (NADPH oxidase-2)-dependent upregulation of GDF6 (growth differentiation factor 6).
A, GDF6 levels in conditioned medium of primary cardiac fibroblasts infected with adenoviruses expressing shRNA (short hairpin RNA) 
targeted against Nox2 (Ad.shNox2) or adenoviruses expressing shRNA targeted against a GFP (green fluorescent protein) control (Ad.shGFP; 
control) and treated with ANG II (angiotensin II) or vehicle. Representative immunoblot shown at the top and mean data at the bottom; n=3 
per group. Ponceau staining of the membrane is shown in Figure XI in the Data Supplement. B, GDF6 protein levels in aorta from Fibro-
Nox2KO or matched control (Nox2Flox) mice chronically treated with ANG II or saline vehicle. Representative immunoblot shown at the top 
and mean data at the bottom; n=4 per group. β-actin was used as a loading control. Densitometry values for GDF6-specific bands were 
divided by the corresponding densitometry of Ponceau bands in A and β-actin bands in B. Arbitrary units were calculated by normalizing data 
vs the control group (ie, fold-change). C, GDF6 immunostaining in aorta from Fibro-Nox2KO and control mice treated with ANG II or saline. 
Representative images are shown on the left and mean fluorescence intensity on the right. GDF6, red; 4′-6-diamidino-2-phenylindole (DAPI), 
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which was Nox2- and ROS-dependent. This action did not 
involve the direct effects of hydrogen peroxide diffusing 
from fibroblasts to VSMC. Using a proteomic analysis of 
the secretome of ANG II–stimulated cultured fibroblasts 
along with bioinformatic analysis, we homed down on a 
small number of putative fibroblast-specific candidate fac-
tors that might account for the paracrine effect of fibro-
blast-secreted factors on VSMC growth. Among these, the 
TGF-β superfamily member GDF6 was a likely candidate 
given that it was regulated in a Nox2 and ROS-dependent 
manner in the aorta, as well as fibroblasts in vitro. Indeed, 
we found evidence of Nox2-dependent release of GDF6 
into the secretome of ANG II–stimulated fibroblasts as well 
as increased GDF6 protein levels and immunoreactivity in 
the aorta of control mice stimulated with ANG II but not 
Fibro-Nox2KO animals. Finally, recombinant GDF6 signifi-
cantly increased VSMC growth in vitro, and the silencing 
of GDF6 in fibroblasts prevented the effects of fibroblast-
conditioned media on VSMC.
GDF6 is a member of the TGF-β superfamily of proteins 
and is known to be involved in regulating ocular and skel-
etal development in multiple species including humans.28–31 
Eye disorders that are linked to GDF6 mutations include 
microphthalmia and age-related macular degeneration.29,31 
Abnormalities of skeletal development linked to GDF6 
mutations include vertebral fusion and abnormal joint devel-
opment, for example, in the Klippel-Feil syndrome.30 Very 
little is known about the function of GDF6 in the cardio-
vascular system apart from a very recent report suggesting 
a role in vascular stabilization in zebrafish.32 However, as a 
member of the TGF-β superfamily that is reported to signal 
through the phosphorylation of SMAD (similar to mothers 
against decapentaplegic) transcription factors,33 a growth 
role is predictable. Other TGF-β superfamily members such 
as TGF-β1-3 have been implicated in vascular remodel-
ing but we did not detect significant levels of TGF-β in 
the conditioned medium of ANG II–treated fibroblasts, 
although mRNA levels were reduced in fibroblasts after 
knockdown of Nox2. Nevertheless, we cannot discount the 
possibility that the fibroblast-mediated enhancement of 
vascular medial thickening observed in the current study 
may involve the action of GDF6 in combination with other 
secreted factors. It is also possible that Nox2-dependent 
inactivation of endothelial nitric oxide could synergize with 
such effects given that nitric oxide has inhibitory effects on 
VSMC growth.34 The mechanism by which Nox2 increases 
the release of GDF6 from fibroblasts requires further study 
but appears to be transcriptional and redox-dependent 
because we found an inhibition of the ANG II–induced 
increase in GDF6 mRNA levels when Nox2 was knocked 
down or the cells were incubated with superoxide dis-
mutase and catalase.
In summary, this study identifies a novel paracrine-sig-
naling mechanism involving fibroblast Nox2-dependent 
secretion of GDF6, which promotes vascular remodeling 
and hypertension in response to chronic ANG II eleva-
tion (Graphic abstract). The timing of effect of fibroblast 
Nox2 on ANG II–induced hypertension contrasts to the 
effects of endothelial Nox2 studied in the same model, 
which occur earlier and are related to altered vascular 
tone.16 Our results add to the emerging concept of Nox2 
as a master regulator of ANG II–induced hypertension 
and also suggest that GDF6 could be a potential target 
to inhibit vascular remodeling during increased activation 
of the renin-angiotensin system.
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Figure 6. GDF6 (growth differentiation factor 6) induces 
vascular smooth muscle cell (VSMC) growth.
A, Concentration-dependent effect of recombinant GDF6 (0–4 µg/mL) 
on BrdU (bromodeoxyuridine) incorporation in VSMC; n=4–6 per group. 
B, Representative Western blot for GDF6 expression after silencing 
using siRNA (silencing RNA) against GDF6 or scrambled control 
(control) in primary cardiac fibroblasts. C and D, VSMC growth assessed 
by Ki67 staining after incubation with conditioned media of aortic (C) 
or cardiac (D) fibroblasts treated with ANG II (angiotensin II). Some 
fibroblasts were treated with siGDF6 (silencing RNA against GDF6) to 
reduce GDF6 levels. 1-way ANOVA followed by Tukey post-test (A and 
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